Fibrocell Science Inc (NASDAQ:FCSC) posted its quarterly earnings results on Wednesday. The company reported ($0.31) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.31), reports. Fibrocell Science had a negative net margin of 4,307.60% and a negative return on equity of 194.12%.

Fibrocell Science (NASDAQ:FCSC) traded down 10.2574% during mid-day trading on Friday, hitting $2.7192. 60,162 shares of the company traded hands. Fibrocell Science has a one year low of $0.52 and a one year high of $4.64. The firm’s market capitalization is $39.95 million. The firm has a 50 day moving average of $3.62 and a 200 day moving average of $2.23.

FCSC has been the topic of several analyst reports. ValuEngine lowered shares of Fibrocell Science from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. HC Wainwright reiterated a “buy” rating and set a $5.70 price target on shares of Fibrocell Science in a research report on Friday, June 9th. Finally, Zacks Investment Research upgraded shares of Fibrocell Science from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a research report on Wednesday, July 12th.

TRADEMARK VIOLATION WARNING: “Fibrocell Science Inc (FCSC) Posts Quarterly Earnings Results, Hits Expectations” was published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at

An institutional investor recently raised its position in Fibrocell Science stock. Creative Planning increased its position in Fibrocell Science Inc (NASDAQ:FCSC) by 395.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 61,090 shares of the company’s stock after buying an additional 48,755 shares during the period. Creative Planning owned about 0.42% of Fibrocell Science worth $245,000 as of its most recent filing with the SEC. 55.31% of the stock is owned by hedge funds and other institutional investors.

Fibrocell Science Company Profile

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

Earnings History for Fibrocell Science (NASDAQ:FCSC)

Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.